RETMARKER
Retmarker, a patented and certified medical device, is a biomarker for Diabetic Retinopathy progression. Diabetic Retinopathy is the eye-sight complication of Diabetes (382 Million today and 592 Millions estimated in 2035) and the leading cause of blindness in the working population. To avoid blindness, all Diabetics should be screened at least once a year in order to provide early and timely treatment. Retmarker has been used with success in Diabetic Retinopathy Screening Programs since 2011. The aim of Retmarker is not to replace doctors and specialists, rather to provide efficient solutions that empower them to provide the best healthcare to those threatened by Diabetic Retinopathy.
RETMARKER
Industry:
Artificial Intelligence Health Care Machine Learning Medical
Founded:
2008-12-01
Address:
Coimbra, Coimbra, Portugal
Country:
Portugal
Website Url:
http://www.retmarker.com
Total Employee:
1+
Status:
Active
Contact:
+239 989 140
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon WordPress Font Awesome Domain Not Resolving Wordpress Plugins Nginx Sitelinks Search Box Euro
Similar Organizations
Current Employees Featured
Founder
Newest Events participated
Participated in Web Summit 2017
on 2017-11-06 as exhibitor
Official Site Inspections
http://www.retmarker.com
- Host name: pod029.cloudkey.pt
- IP address: 213.58.230.133
- Location: Linda a Velha Portugal
- Latitude: 38.7145
- Longitude: -9.2422
- Timezone: Europe/Lisbon
- Postal: 2795-087
More informations about "Retmarker"
Retmarker - Automated AI technology for vision loss …
The Retmarker company develops proprietary Artificial Intelligence technology that helps to screen and monitor retinal diseases.See details»
Retmarker - Company History
Founded more than 10 years ago as a spin off from Critical Software, the Retmarker company brings the innovative spirit from its founders to push for the adoption of state-of-the-art Artificial …See details»
Retmarker - Crunchbase Company Profile & Funding
Retmarker, a patented and certified medical device, is a biomarker for Diabetic Retinopathy progression. Diabetic Retinopathy is the eye-sight complication of Diabetes (382 Million today …See details»
Retmarker
Retmarker enables the implementation of highly efficient and reliable diabetic retinopathy screening programs. Retmarker is a CE-approved software medical device.See details»
Retmarker Company Profile 2024: Valuation, Investors
Developer of medical devices designed to offer an efficient screening of diabetic retinopathy. The company's devices monitor the progression of retinal diseases leading to blindness, enabling …See details»
RETMARKER, S.A. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for RETMARKER, S.A. of TAVEIRO, COIMBRA. Get the latest business insights from Dun & Bradstreet.See details»
Meteda acquires Retmarker - 2022-01-19 - Crunchbase
Jan 19, 2022 · Retmarker Retmarker artificial intelligence technology makes the Diabetic Retinopathy annual screening objective, scalable and affordable. Acquiring Organization: …See details»
Retmarker - Retmarker DR Screening
Highly reliable and affordable Diabetic Retinopathy Screening technology to those providing DR Screening services.See details»
Retmarker - Products, Competitors, Financials, Employees, …
Retmarker is a patented and certified medical device with a biomarker for Diabetic Retinopathy progression. On January 19th, 2022, Retmarker was acquired by Meteda. Use the CB Insights …See details»
Artificial Intelligence and Diabetic Retinopathy: AI …
Sep 20, 2023 · The study findings showed that human graders had a greater positive predictive value and negative predictive value than EyeArt and Retmarker. In this cohort, EyeArt had a sensitivity of 93.8% for any retinopathy …See details»
Retmarker - Contacts, Employees, Board Members, …
Retmarker artificial intelligence technology makes the Diabetic Retinopathy annual screening objective, scalable and affordable.See details»
AI technologies for detecting diabetic retinopathy - NICE
EyeArt (Eyenuk), RetinaLyze (RetinaLyze System A/S) and Retmarker (Retmarker) use artificial intelligence (AI) technology to analyse retinal images to help diagnose diabetic retinopathy.See details»
Retmarker - Retmarker DR Biomarker
RetmarkerDR consistently tracks each microaneurysm as a single entity in a specific location, with identifiable coordinates, providing valuable information. The MA is classified as New (Red), …See details»
AI technologies for detecting diabetic retinopathy - NICE
Jul 6, 2021 · EyeArt and Retmarker are CE marked class IIa medical devices. RetinaLyze is a CE marked class I (self-certified) medical device.See details»
Validation of RetmarkerAMD as a semiautomatic grading …
Oct 23, 2019 · By conducting a carefully planned study, we were able to demonstrate that RetmarkerAMD® is a reliable and consistent semiautomated grading tool for AMD. The …See details»
AI technologies for detecting diabetic retinopathy - NICE
Jul 6, 2021 · EyeArt (Eyenuk), RetinaLyze (RetinaLyze System A/S) and Retmarker (Retmarker) use artificial intelligence (AI) technology to analyse retinal images to help diagnose diabetic …See details»
DR SCREENING - Retmarker
RETMARKER SCREENING IS CURRENTLY CERTIFIED AS A CLASS IIa MEDICAL DEVICE IN EUROPE AND IS ALSO APPROVED IN AUSTRALIA. private practices are being screened in …See details»
Retmarker now available in Europe
May 7, 2010 · Critical Health has announced that Retmarker, its software solution for decision support in the ophthalmology domain, attained the right to hold the CE 0197 branding, that …See details»
Retmarker | Coimbra - Facebook
Retmarker, Coimbra, Portugal. 954 likes. RETMARKER - Innovation in Vision Loss PreventionSee details»
Retmarker - Retmarker DR Biomarker
RETMARKER Biomarker IS CURRENTLY CERTIFIED AS A CLASS IIa MEDICAL DEVICE IN EUROPE. We're ready, challenge us! World's first software biomarker that predicts the risk of …See details»